中国肺癌杂志2012，Vol.15Issue(9)：507-512,6.DOI:10.3779/j.issn.1009-3419.2012.09.02
吉西他滨联合长春瑞滨方案治疗复治中国晚期非小细胞肺癌患者的多中心回顾性研究
Gemcitabine Combined with Vinorelbine in the Treatment of Refractory Patients with Advanced Non-small Cell Lung Cancer: A Multi-center Retrospective Study
陆舜 1张力 2虞永峰 1陈公琰 3赵青4
作者信息
- 1. 200030上海,上海交通大学附属胸科医院肺部肿瘤临床医学中心
- 2. 510060广州,中山大学肿瘤医院肿瘤科
- 3. 150081哈尔滨,哈尔滨医科大学附属肿瘤医院
- 4. 650032昆明,昆明军区总医院胸外科
- 折叠
摘要
Abstract
Background and objective The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN as second-line or further-line treatment) in refractory advanced non-small cell lung cancer (NSCLC) patients in China. Methods We retrospectively reviewed 53 NSCLC patients treated with this agent at four hospital in China from Jan 01, 2004 to Jun 30, 2010. Survival analysis was evaluated by Kaplan-Meier method. Results A total of 53 patients were analyzed in this study (28 patients in second-line and 25 in third- or further-line treatment). The objective response rate (ORR) was 9.4%. The disease control rate (DCR) was 56-6%. The progression-free survival (PFS) and median overall survival (OS) was 3.0 and 17.6 months, respectively. Univariate analysis, revealed performance status (PS) score was an independent prognostic factor for overall survival. Conclusion The GN agent is effective for the second-line or further-line treatment in advanced non-small cell lung cancer. The toxicity is well tolerated.关键词
吉西他滨/长春瑞滨/化疗/肺肿瘤Key words
Gemcitabine/ Vinorelbine/ Chemotherapy/ Lung neoplasms分类
医药卫生引用本文复制引用
陆舜,张力,虞永峰,陈公琰,赵青..吉西他滨联合长春瑞滨方案治疗复治中国晚期非小细胞肺癌患者的多中心回顾性研究[J].中国肺癌杂志,2012,15(9):507-512,6.
